{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:51:14Z","timestamp":1792007474200,"version":"4.4.0"},"reference-count":134,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T00:00:00Z","timestamp":1691020800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.phrs.2023.106884","type":"journal-article","created":{"date-parts":[[2023,8,6]],"date-time":"2023-08-06T20:26:22Z","timestamp":1691353582000},"page":"106884","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Paradigm shift in the treatment of tuberous sclerosis: Effectiveness of everolimus"],"prefix":"10.1016","volume":"195","author":[{"given":"Roberto","family":"Previtali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Prontera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Alfei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Nespoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Masnada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierangelo","family":"Veggiotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savina","family":"Mannarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.phrs.2023.106884_bib1","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1001\/archneur.57.5.662","article-title":"National institutes of health consensus conference: tuberous sclerosis complex","volume":"57","author":"Hyman","year":"2000","journal-title":"Arch. Neurol."},{"issue":"6","key":"10.1016\/j.phrs.2023.106884_bib2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1017\/S0012162206001058","article-title":"Tuberous sclerosis complex: clinical features, diagnosis, and prevalence within Northern Ireland","volume":"48","author":"Devlin","year":"2006","journal-title":"Dev. Med Child Neurol."},{"key":"10.1016\/j.phrs.2023.106884_bib3","volume":"Vol 68","author":"Dabora","year":"2001","journal-title":"Mutat. Anal. a Cohort 224 Tube Scler. Patients Indic. Increase Sev. TSC2, Comp. TSC1, Dis. Mult. Organs"},{"issue":"6","key":"10.1016\/j.phrs.2023.106884_bib4","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/sj.ejhg.5201402","article-title":"Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype-phenotype correlations and comparison of diagnostic DNA techniques in tuberous sclerosis complex","volume":"13","author":"Sancak","year":"2005","journal-title":"Eur. J. Hum. Genet."},{"issue":"2","key":"10.1016\/j.phrs.2023.106884_bib5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s004390000348","article-title":"Molecular genetic advances in tuberous sclerosis","volume":"107","author":"Cheadle","year":"2000","journal-title":"Hum. Genet"},{"key":"10.1016\/j.phrs.2023.106884_bib6","article-title":"High rate of mosaicism in tuberous sclerosis complex","volume":"Vol 64","author":"Verhoef","year":"1999"},{"issue":"4","key":"10.1016\/j.phrs.2023.106884_bib7","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.pediatrneurol.2013.12.002","article-title":"Mechanism-based treatment in tuberous sclerosis complex","volume":"50","author":"J\u00fclich","year":"2014","journal-title":"Pedia Neurol."},{"issue":"1\u20132","key":"10.1016\/j.phrs.2023.106884_bib8","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/pr.2013.185","article-title":"Emerging role of autophagy in pediatric neurodegenerative and neurometabolic diseases","volume":"75","author":"Ebrahimi-Fakhari","year":"2014","journal-title":"Pedia Res"},{"key":"10.1016\/j.phrs.2023.106884_bib9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semcdb.2016.01.025","article-title":"Tuberous sclerosis\u2014a model for tumour growth","volume":"52","author":"Dodd","year":"2016","journal-title":"Semin Cell Dev. Biol."},{"issue":"14","key":"10.1016\/j.phrs.2023.106884_bib10","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.4161\/cc.10.14.16586","article-title":"mTOR complex 2 signaling and functions","volume":"10","author":"Oh","year":"2011","journal-title":"Cell Cycle"},{"issue":"1","key":"10.1016\/j.phrs.2023.106884_bib11","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/ng0195-70","article-title":"A germline insertion in the tuberous sclerosis (Tsc2) gene gives rise to the Eker rat model of dominantly inherited cancer","volume":"9","author":"Kobayashi","year":"1995","journal-title":"Nat. Genet"},{"key":"10.1016\/j.phrs.2023.106884_bib12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/bs.adgen.2018.11.003","article-title":"Finding a cure for tuberous sclerosis complex: from genetics through to targeted drug therapies","volume":"103","author":"McEneaney","year":"2019","journal-title":"Adv. Genet"},{"issue":"4","key":"10.1016\/j.phrs.2023.106884_bib13","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.pediatrneurol.2013.08.001","article-title":"Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 international tuberous sclerosis complex consensus conference","volume":"49","author":"Northrup","year":"2013","journal-title":"Pedia Neurol."},{"key":"10.1016\/j.phrs.2023.106884_bib14","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.pediatrneurol.2021.07.011","article-title":"Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations","volume":"123","author":"Northrup","year":"2021","journal-title":"Pedia Neurol."},{"key":"10.1016\/j.phrs.2023.106884_bib15","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1146\/annurev-genom-083118-015354","article-title":"Genetic etiologies, diagnosis, and treatment of tuberous sclerosis complex","volume":"20","author":"Salussolia","year":"2019","journal-title":"Annu Rev. Genom. Hum. Genet"},{"key":"10.1016\/j.phrs.2023.106884_bib16","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1474-4422(22)00213-7","article-title":"Advances in the genetics and neuropathology of tuberous sclerosis complex: edging closer to targeted therapy","volume":"21","author":"Curatolo","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.phrs.2023.106884_bib17","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.neuroscience.2016.11.017","article-title":"Molecular neurobiology of mTOR","volume":"341","author":"Switon","year":"2017","journal-title":"Neuroscience"},{"key":"10.1016\/j.phrs.2023.106884_bib18","doi-asserted-by":"crossref","first-page":"5S8","DOI":"10.1016\/S0929-693X(22)00284-6","article-title":"Tuberous sclerosis complex and epilepsy in infancy: prevention and early diagnosis","volume":"29","author":"de Saint Martin","year":"2022","journal-title":"Arch. De. P\u00e9diatrie"},{"issue":"7","key":"10.1016\/j.phrs.2023.106884_bib19","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/j.1528-1167.2009.02474.x","article-title":"The natural history of epilepsy in tuberous sclerosis complex","volume":"51","author":"Chu-Shore","year":"2010","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.phrs.2023.106884_bib20","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1528-1167.2010.02892.x","article-title":"Cerebral tuber count and its impact on mental outcome of patients with tuberous sclerosis complex","volume":"52","author":"Kaczorowska","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.phrs.2023.106884_bib21","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S1474-4422(15)00069-1","article-title":"Neurological and neuropsychiatric aspects of tuberous sclerosis complex","volume":"14","author":"Curatolo","year":"2015","journal-title":"Lancet Neurol."},{"issue":"6","key":"10.1016\/j.phrs.2023.106884_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157396","article-title":"Novel histopathological patterns in cortical tubers of epilepsy surgery patients with tuberous sclerosis complex","volume":"11","author":"M\u00fchlebner","year":"2016","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.phrs.2023.106884_bib23","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1093\/jnen\/nlaa090","article-title":"Myelin pathology beyond white matter in tuberous sclerosis complex (TSC) cortical tubers","volume":"79","author":"M\u00fchlebner","year":"2020","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"2","key":"10.1016\/j.phrs.2023.106884_bib24","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.braindev.2008.09.013","article-title":"Recent advances in neurobiology of tuberous sclerosis complex","volume":"31","author":"Napolioni","year":"2009","journal-title":"Brain Dev."},{"issue":"13","key":"10.1016\/j.phrs.2023.106884_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22136677","article-title":"Brain symptoms of tuberous sclerosis complex: pathogenesis and treatment","volume":"22","author":"Mizuguchi","year":"2021","journal-title":"Int J. Mol. Sci."},{"issue":"13","key":"10.1016\/j.phrs.2023.106884_bib26","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S1470-2045(14)70489-9","article-title":"Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study","volume":"15","author":"Franz","year":"2014","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.phrs.2023.106884_bib27","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0025-6196(12)61196-3","article-title":"Causes of death in patients with tuberous sclerosis","volume":"66","author":"Shepherd","year":"1991","journal-title":"Mayo Clin. Proc."},{"issue":"1","key":"10.1016\/j.phrs.2023.106884_bib28","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.pediatrneurol.2014.10.004","article-title":"Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND Checklist","volume":"52","author":"de Vries","year":"2015","journal-title":"Pedia Neurol."},{"key":"10.1016\/j.phrs.2023.106884_bib29","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.yebeh.2017.02.007","article-title":"Influence of seizures on early development in tuberous sclerosis complex","volume":"70","author":"Capal","year":"2017","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.phrs.2023.106884_bib30","doi-asserted-by":"crossref","DOI":"10.1177\/2329048X17725609","article-title":"Implementing a multidisciplinary approach to treating tuberous sclerosis complex","volume":"4","author":"Gipson","year":"2017","journal-title":"Child Neurol. Open"},{"issue":"1","key":"10.1016\/j.phrs.2023.106884_bib31","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40272-019-00376-0","article-title":"Update on drug management of refractory epilepsy in tuberous sclerosis complex","volume":"22","author":"van der Poest Clement","year":"2020","journal-title":"Pediatr. Drugs"},{"issue":"4","key":"10.1016\/j.phrs.2023.106884_bib32","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.carpath.2007.08.008","article-title":"Pediatric heart tumors","volume":"17","author":"Burke","year":"2008","journal-title":"Cardiovasc Pathol."},{"key":"10.1016\/j.phrs.2023.106884_bib33","doi-asserted-by":"crossref","DOI":"10.1186\/1750-1172-2-11","article-title":"Cardiac tumours in children","volume":"2","author":"Uzun","year":"2007","journal-title":"Orphanet J. Rare Dis."},{"issue":"6","key":"10.1016\/j.phrs.2023.106884_bib34","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001493","article-title":"Cardiovascular manifestations of tuberous sclerosis complex and summary of the revised diagnostic criteria and surveillance and management recommendations from the International Tuberous Sclerosis Consensus Group","volume":"3","author":"Hinton","year":"2014","journal-title":"J. Am. Heart Assoc."},{"issue":"10","key":"10.1016\/j.phrs.2023.106884_bib35","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1055\/s-0029-1223267","article-title":"Perinatal (fetal and neonatal) tuberous sclerosis: a review","volume":"26","author":"Isaacs","year":"2009","journal-title":"Am. J. Perinatol."},{"issue":"18","key":"10.1016\/j.phrs.2023.106884_bib36","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.jacc.2011.08.005","article-title":"Cardiac tumors and associated arrhythmias in pediatric patients, with observations on surgical therapy for ventricular tachycardia","volume":"58","author":"Miyake","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.phrs.2023.106884_bib37","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/adc.78.2.159","article-title":"Tuberous sclerosis complex and Wolff-Parkinson-White syndrome","volume":"78","author":"O\u2019Callaghan","year":"1998","journal-title":"Arch. Dis. Child"},{"issue":"9","key":"10.1016\/j.phrs.2023.106884_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph18094907","article-title":"Treatment of cardiac rhabdomyomas with mtor inhibitors in children with tuberous sclerosis complex-a systematic review","volume":"18","author":"Sugalska","year":"2021","journal-title":"Int J. Environ. Res Public Health"},{"issue":"3","key":"10.1016\/j.phrs.2023.106884_bib39","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.pcl.2015.03.005","article-title":"Tuberous sclerosis complex","volume":"62","author":"DiMario","year":"2015","journal-title":"Pedia Clin. North Am."},{"issue":"3","key":"10.1016\/j.phrs.2023.106884_bib40","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/path.2289","article-title":"Constant allelic alteration on chromosome 16p (TSC2 gene) in perivascular epithelioid cell tumour (PEComa): genetic evidence for the relationship of PEComa with angiomyolipoma","volume":"214","author":"Pan","year":"2008","journal-title":"J. Pathol."},{"key":"10.1016\/j.phrs.2023.106884_bib41","series-title":"In: Pediatric Nephrology","first-page":"1120","article-title":"Renal angiomyolipoma","author":"Cooper","year":"2004"},{"issue":"9","key":"10.1016\/j.phrs.2023.106884_bib42","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1177\/08830738040190091001","article-title":"Non-neurologic manifestations of tuberous sclerosis complex","volume":"19","author":"Neal Franz","year":"2004","journal-title":"J. Child Neurol."},{"issue":"4","key":"10.1016\/j.phrs.2023.106884_bib43","first-page":"e166","article-title":"Tuberous sclerosis complex: a review","volume":"46","author":"Randle","year":"2017","journal-title":"Pedia Ann."},{"issue":"1","key":"10.1016\/j.phrs.2023.106884_bib44","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-022-02266-0","article-title":"Perfect match: mTOR inhibitors and tuberous sclerosis complex","volume":"17","author":"Luo","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"issue":"10","key":"10.1016\/j.phrs.2023.106884_bib45","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1001\/jamadermatol.2014.938","article-title":"Dermatologic and dental aspects of the 2012 international tuberous sclerosis complex consensus statements","volume":"150","author":"Teng","year":"2014","journal-title":"JAMA Dermatol."},{"issue":"12","key":"10.1016\/j.phrs.2023.106884_bib46","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1046\/j.1365-4362.1998.00495.x","article-title":"Skin lesions in children with tuberous sclerosis complex: their prevalence, natural course, and diagnostic significance","volume":"37","author":"J\u00f3zwiak","year":"1998","journal-title":"Int J. Dermatol."},{"issue":"9639","key":"10.1016\/j.phrs.2023.106884_bib47","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(08)61279-9","article-title":"Tuberous sclerosis","volume":"372","author":"Curatolo","year":"2008","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.phrs.2023.106884_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2133.1996.d01-923.x","article-title":"The cutaneous features of tuberous sclerosis: a population study","volume":"135","author":"Webb","year":"1996","journal-title":"Br. J. Dermatol."},{"issue":"9","key":"10.1016\/j.phrs.2023.106884_bib49","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1177\/08830738040190090301","article-title":"Diagnosis of tuberous sclerosis complex","volume":"19","author":"Roach","year":"2004","journal-title":"J. Child Neurol."},{"issue":"1","key":"10.1016\/j.phrs.2023.106884_bib50","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/ceo.12806","article-title":"Ophthalmic manifestations of tuberous sclerosis: a review","volume":"45","author":"Hodgson","year":"2017","journal-title":"Clin. Exp. Ophthalmol."},{"issue":"12","key":"10.1016\/j.phrs.2023.106884_bib51","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1177\/088307389801301206","article-title":"Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria","volume":"13","author":"Roach","year":"1998","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.phrs.2023.106884_bib52","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/B978-0-444-62702-5.00006-8","article-title":"Tuberous sclerosis complex","volume":"132","author":"Islam","year":"2015","journal-title":"Handb. Clin. Neurol."},{"issue":"2","key":"10.1016\/j.phrs.2023.106884_bib53","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1378\/chest.12-2813","article-title":"Lymphangioleiomyomatosis screening in women with tuberous sclerosis","volume":"144","author":"Cudzilo","year":"2013","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.phrs.2023.106884_bib54","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1002\/ajmg.a.38260","article-title":"Sclerotic bone lesions in tuberous sclerosis complex: a genotype\u2013phenotype study","volume":"173","author":"Boronat","year":"2017","journal-title":"Am. J. Med Genet A"},{"key":"10.1016\/j.phrs.2023.106884_bib55","first-page":"858","article-title":"Tuberous sclerosis","author":"Tsao","year":"2003","journal-title":": Dermatol. Mosby"},{"issue":"5","key":"10.1016\/j.phrs.2023.106884_bib56","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/ana.23960","article-title":"Everolimus treatment of refractory epilepsy in tuberous sclerosis complex","volume":"74","author":"Krueger","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.phrs.2023.106884_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/17562864211031100","article-title":"Review of the treatment options for epilepsy in tuberous sclerosis complex: towards precision medicine","volume":"14","author":"Schubert-Bast","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"7","key":"10.1016\/j.phrs.2023.106884_bib58","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S2352-4642(18)30099-3","article-title":"Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial","volume":"2","author":"Curatolo","year":"2018","journal-title":"Lancet Child Adolesc. Health"},{"issue":"2","key":"10.1016\/j.phrs.2023.106884_bib59","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.25956","article-title":"Prevention of epilepsy in infants with tuberous sclerosis complex in the EPISTOP Trial","volume":"89","author":"Kotulska","year":"2021","journal-title":"Ann. Neurol."},{"issue":"10","key":"10.1016\/j.phrs.2023.106884_bib60","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1111\/j.1528-1167.2005.00266.x","article-title":"Tuberous sclerosis complex and the ketogenic diet","volume":"46","author":"Kossoff","year":"2005","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.phrs.2023.106884_bib61","doi-asserted-by":"crossref","first-page":"45","DOI":"10.14581\/jer.17008","article-title":"Ketogenic diet for the management of epilepsy associated with tuberous sclerosis complex in children","volume":"7","author":"Park","year":"2017","journal-title":"J. Epilepsy Res"},{"key":"10.1016\/j.phrs.2023.106884_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2020.106348","article-title":"Long-term outcomes of ketogenic diet in patients with tuberous sclerosis complex-derived epilepsy","volume":"164","author":"Youn","year":"2020","journal-title":"Epilepsy Res"},{"issue":"2","key":"10.1016\/j.phrs.2023.106884_bib63","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/epi.17150","article-title":"Long-term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open-label extension trial","volume":"63","author":"Thiele","year":"2022","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.phrs.2023.106884_bib64","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ejpn.2018.05.006","article-title":"Management of epilepsy associated with tuberous sclerosis complex: updated clinical recommendations","volume":"22","author":"Curatolo","year":"2018","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"3","key":"10.1016\/j.phrs.2023.106884_bib65","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.eplepsyres.2013.02.016","article-title":"Predictors of seizure freedom after surgical management of tuberous sclerosis complex: a systematic review and meta-analysis","volume":"105","author":"Zhang","year":"2013","journal-title":"Epilepsy Res"},{"issue":"8","key":"10.1016\/j.phrs.2023.106884_bib66","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s00381-019-04255-4","article-title":"Laser and the Tuber\u201d: thermal dynamic and volumetric factors influencing seizure outcomes in pediatric subjects with tuberous sclerosis undergoing stereoencephalography-directed laser ablation of tubers","volume":"35","author":"Stellon","year":"2019","journal-title":"Child\u2019s Nerv. Syst."},{"key":"10.1016\/j.phrs.2023.106884_bib67","article-title":"Newly diagnosed and growing subependymal giant cell astrocytoma in adults with tuberous sclerosis complex: results from the international TOSCA Study","volume":"10","author":"Jansen","year":"2019","journal-title":"Front Neurol."},{"issue":"4","key":"10.1016\/j.phrs.2023.106884_bib68","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.pediatrneurol.2013.08.002","article-title":"Tuberous sclerosis complex surveillance and management: recommendations of the 2012 international tuberous sclerosis complex consensus conference","volume":"49","author":"Krueger DA","year":"2013","journal-title":"Pedia Neurol."},{"issue":"1","key":"10.1016\/j.phrs.2023.106884_bib69","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-021-01800-w","article-title":"Involvement of mental health professionals in the treatment of tuberous sclerosis complex-associated neuropsychiatric disorders (TAND): results of a multinational European electronic survey","volume":"16","author":"Waltereit","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.phrs.2023.106884_bib70","first-page":"1","article-title":"Regression of cardiac rhabdomyomas in a neonate after everolimus treatment","volume":"2016","author":"Bornaun","year":"2016","journal-title":"Case Rep. Pedia"},{"issue":"8","key":"10.1016\/j.phrs.2023.106884_bib71","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/j.1651-2227.1996.tb14188.x","article-title":"The natural history of cardiac rhabdomyoma with and without tuberous sclerosis","volume":"85","author":"Bosi","year":"1996","journal-title":"Acta Paediatr."},{"issue":"3","key":"10.1016\/j.phrs.2023.106884_bib72","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/ajmg.c.31638","article-title":"Pulmonary manifestations in tuberous sclerosis complex","volume":"178","author":"Gupta","year":"2018","journal-title":"Am. J. Med Genet C. Semin Med Genet"},{"issue":"5","key":"10.1016\/j.phrs.2023.106884_bib73","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s40265-016-0552-9","article-title":"The Role of mTOR inhibitors in the treatment of patients with tuberous sclerosis complex: evidence-based and expert opinions","volume":"76","author":"Curatolo","year":"2016","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.phrs.2023.106884_bib74","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.ejpn.2012.05.004","article-title":"Management of epilepsy associated with tuberous sclerosis complex (TSC): Clinical recommendations","volume":"16","author":"Curatolo","year":"2012","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"3","key":"10.1016\/j.phrs.2023.106884_bib75","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/ana.20784","article-title":"Rapamycin causes regression of astrocytomas in tuberous sclerosis complex","volume":"59","author":"Franz","year":"2006","journal-title":"Ann. Neurol."},{"issue":"19","key":"10.1016\/j.phrs.2023.106884_bib76","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","article-title":"Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis from the departments of pediatrics and neurology D","volume":"4","author":"Krueger","year":"2010","journal-title":"N. Engl. J. Med"},{"issue":"8","key":"10.1016\/j.phrs.2023.106884_bib77","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s00381-011-1406-0","article-title":"The management of subependymal giant cell tumors in tuberous sclerosis: a clinician\u2019s perspective","volume":"27","author":"Moavero","year":"2011","journal-title":"Child\u2019s Nerv. Syst."},{"issue":"1","key":"10.1016\/j.phrs.2023.106884_bib78","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00381-010-1222-y","article-title":"Regression of subependymal giant cell astrocytomas with RAD001 (Everolimus) in tuberous sclerosis complex","volume":"27","author":"Yalon","year":"2011","journal-title":"Child\u2019s Nerv. Syst."},{"issue":"1","key":"10.1016\/j.phrs.2023.106884_bib79","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejpn.2011.09.006","article-title":"Effective everolimus treatment of inoperable, life-threatening subependymal giant cell astrocytoma and intractable epilepsy in a patient with tuberous sclerosis complex","volume":"16","author":"Perek-Polnik","year":"2012","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"9861","key":"10.1016\/j.phrs.2023.106884_bib80","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): A multicentre, randomised, placebo-controlled phase 3 trial","volume":"381","author":"Franz","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2023.106884_bib81","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.581102","article-title":"Maintenance therapy with everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis \u2013 final results from the EMINENTS Study","volume":"12","author":"Bobeff","year":"2021","journal-title":"Front Neurol."},{"issue":"11","key":"10.1016\/j.phrs.2023.106884_bib82","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1080\/14656566.2020.1751124","article-title":"Pharmacological treatment strategies for subependymal giant cell astrocytoma (SEGA)","volume":"21","author":"Ebrahimi-Fakhari","year":"2020","journal-title":"Expert Opin. Pharm."},{"issue":"5","key":"10.1016\/j.phrs.2023.106884_bib83","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.jpeds.2013.12.053","article-title":"Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex","volume":"164","author":"Cardamone","year":"2014","journal-title":"J. Pedia"},{"key":"10.1016\/j.phrs.2023.106884_bib84","author":"Krueger","year":"2013","journal-title":"Everolimus Long. -Term. Saf. Effic. Subependymal Giant Cell Astro"},{"issue":"1","key":"10.1016\/j.phrs.2023.106884_bib85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-016-0530-z","article-title":"Efficacy and safety of Everolimus in children with TSC - associated epilepsy - pilot data from an open single-center prospective study","volume":"11","author":"Samueli","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"issue":"10056","key":"10.1016\/j.phrs.2023.106884_bib86","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","article-title":"Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study","volume":"388","author":"French","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.phrs.2023.106884_bib87","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/epi.14085","article-title":"Everolimus dosing recommendations for tuberous sclerosis complex\u2013associated refractory seizures","volume":"59","author":"Franz","year":"2018","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.phrs.2023.106884_bib88","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1212\/CPJ.0000000000000514","article-title":"Everolimus for treatment-refractory seizures in TSC: extension of a randomized controlled trial","volume":"8","author":"Franz","year":"2018","journal-title":"Neurol. Clin. Pr."},{"issue":"9","key":"10.1016\/j.phrs.2023.106884_bib89","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1111\/epi.14529","article-title":"Everolimus in infants with tuberous sclerosis complex\u2013related West syndrome: First results from a single-center prospective observational study","volume":"59","author":"Samueli","year":"2018","journal-title":"Epilepsia"},{"issue":"9","key":"10.1016\/j.phrs.2023.106884_bib90","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/bdd.524","article-title":"Everolimus drug interactions: application of a classification system for clinical decision making","volume":"27","author":"Kovarik","year":"2006","journal-title":"Biopharm. Drug Dispos."},{"issue":"6","key":"10.1016\/j.phrs.2023.106884_bib91","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/epi.14085","article-title":"Everolimus dosing recommendations for tuberous sclerosis complex-associated refractory seizures","volume":"59","author":"Franz","year":"2018","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.phrs.2023.106884_bib92","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1345\/aph.1A384","article-title":"Effect of rifampin on apparent clearance of everolimus","volume":"36","author":"Kovarik","year":"2002","journal-title":"Ann. Pharmacother."},{"issue":"06","key":"10.1016\/j.phrs.2023.106884_bib93","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1055\/s-0039-1695786","article-title":"Cannabidiol interacts significantly with everolimus\u2014report of a patient with tuberous sclerosis complex","volume":"50","author":"Wiemer-Kruel","year":"2019","journal-title":"Neuropediatrics"},{"issue":"12","key":"10.1016\/j.phrs.2023.106884_bib94","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/acn3.494","article-title":"Everolimus for treatment of tuberous sclerosis complex-associated neuropsychiatric disorders","volume":"4","author":"Krueger","year":"2017","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"2","key":"10.1016\/j.phrs.2023.106884_bib95","doi-asserted-by":"crossref","first-page":"E200","DOI":"10.1212\/WNL.0000000000007749","article-title":"A randomized controlled trial with everolimus for IQ and autism in tuberous sclerosis complex","volume":"93","author":"Overwater","year":"2019","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.phrs.2023.106884_bib96","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1089\/cap.2016.0100","article-title":"Beneficial effects of everolimus on autism and attention-deficit\/hyperactivity disorder symptoms in a group of patients with tuberous sclerosis complex","volume":"27","author":"Kilincaslan","year":"2017","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2023.106884_bib97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.braindev.2018.07.003","article-title":"Everolimus for epilepsy and autism spectrum disorder in tuberous sclerosis complex: EXIST-3 substudy in Japan","volume":"41","author":"Mizuguchi","year":"2019","journal-title":"Brain Dev."},{"issue":"2","key":"10.1016\/j.phrs.2023.106884_bib98","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/dmcn.12044","article-title":"Understanding relationships between autism, intelligence, and epilepsy: a cross-disorder approach","volume":"55","author":"van Eeghen","year":"2013","journal-title":"Dev. Med Child Neurol."},{"issue":"2","key":"10.1016\/j.phrs.2023.106884_bib99","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1212\/WNL.0000000000007744","article-title":"Everolimus for cognition\/autism in children with tuberous sclerosis complex: Definitive outcomes deferred","volume":"93","author":"Ess","year":"2019","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.phrs.2023.106884_bib100","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1542\/peds.2011-3476","article-title":"Everolimus: a Challenging Drug in the Treatment of Multifocal Inoperable Cardiac Rhabdomyoma","volume":"130","author":"Demir","year":"2012","journal-title":"Pediatrics"},{"issue":"12","key":"10.1016\/j.phrs.2023.106884_bib101","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1111\/echo.13015","article-title":"Oral everolimus for treatment of a giant left ventricular rhabdomyoma in a neonate-rapid tumor regression documented by real time 3d echocardiography","volume":"32","author":"Wagner","year":"2015","journal-title":"Echocardiography"},{"issue":"2","key":"10.1016\/j.phrs.2023.106884_bib102","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s00246-016-1528-y","article-title":"Accelerated cardiac rhabdomyoma regression with everolimus in infants with tuberous sclerosis complex","volume":"38","author":"Aw","year":"2017","journal-title":"Pedia Cardiol."},{"issue":"3","key":"10.1016\/j.phrs.2023.106884_bib103","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s40272-019-00337-7","article-title":"Off-label use of sirolimus and everolimus in a pediatric center: a case series and review of the literature","volume":"21","author":"Bevacqua","year":"2019","journal-title":"Pediatr. Drugs"},{"issue":"1","key":"10.1016\/j.phrs.2023.106884_bib104","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3390\/pediatric13010015","article-title":"Efficacy of everolimus low-dose treatment for cardiac rhabdomyomas in neonatal tuberous sclerosis: case report and literature review","volume":"13","author":"Nespoli","year":"2021","journal-title":"Pedia Rep."},{"issue":"nov26 1","key":"10.1016\/j.phrs.2023.106884_bib105","article-title":"Oral everolimus treatment in a preterm infant with multifocal inoperable cardiac rhabdomyoma associated with tuberous sclerosis complex and a structural heart defect","volume":"2014","author":"Mohamed","year":"2014","journal-title":"Case Rep."},{"key":"10.1016\/j.phrs.2023.106884_bib106","article-title":"Cardiac rhabdomyomas in tuberous sclerosis complex","volume":"192","author":"Castro-Monsalve","year":"2018","journal-title":"J. Pedia"},{"issue":"6","key":"10.1016\/j.phrs.2023.106884_bib107","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/ped.14472","article-title":"Use of everolimus for cardiac rhabdomyomas in a very\u2010low\u2010birthweight infant","volume":"63","author":"Tsuchihashi","year":"2021","journal-title":"Pediatr. Int."},{"issue":"9","key":"10.1016\/j.phrs.2023.106884_bib108","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.3390\/ijerph18094907","article-title":"Treatment of cardiac rhabdomyomas with mTOR inhibitors in children with tuberous sclerosis complex\u2014a systematic review","volume":"18","author":"Sugalska","year":"2021","journal-title":"Int J. Environ. Res Public Health"},{"issue":"2","key":"10.1016\/j.phrs.2023.106884_bib109","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s00246-016-1528-y","article-title":"Accelerated cardiac rhabdomyoma regression with everolimus in infants with tuberous sclerosis complex","volume":"38","author":"Aw","year":"2017","journal-title":"Pedia Cardiol."},{"issue":"7","key":"10.1016\/j.phrs.2023.106884_bib110","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1017\/S1047951114002261","article-title":"Everolimus treatment of a newborn with rhabdomyoma causing severe arrhythmia","volume":"25","author":"\u00d6ztun\u00e7","year":"2015","journal-title":"Cardiol. Young-.-."},{"issue":"5","key":"10.1016\/j.phrs.2023.106884_bib111","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1002\/ajmg.a.62120","article-title":"Everolimus for severe arrhythmias in tuberous sclerosis complex related cardiac rhabdomyomas","volume":"185","author":"Silva\u2010S\u00e1nchez","year":"2021","journal-title":"Am. J. Med Genet A"},{"issue":"1","key":"10.1016\/j.phrs.2023.106884_bib112","doi-asserted-by":"crossref","first-page":"58","DOI":"10.4103\/apc.apc_11_21","article-title":"Use of Everolimus to treat cardiac rhabdomyomas and incessant arrhythmias in a newborn: Benefits and complications","volume":"15","author":"Sagiv","year":"2022","journal-title":"Ann. Pedia Cardiol."},{"issue":"9869","key":"10.1016\/j.phrs.2023.106884_bib113","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): A multicentre, randomised, double-blind, placebo-controlled trial","volume":"381","author":"Bissler","year":"2013","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.phrs.2023.106884_bib114","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.3390\/ijerph18094907","article-title":"Treatment of cardiac rhabdomyomas with mTOR inhibitors in children with tuberous sclerosis complex\u2014a systematic review","volume":"18","author":"Sugalska","year":"2021","journal-title":"Int J. Environ. Res Public Health"},{"issue":"3","key":"10.1016\/j.phrs.2023.106884_bib115","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1017\/S1047951119003147","article-title":"Everolimus for cardiac rhabdomyomas in children with tuberous sclerosis. The ORACLE study protocol (everOlimus for caRdiac rhAbdomyomas in tuberous sCLErosis): a randomised, multicentre, placebo-controlled, double-blind phase II trial","volume":"30","author":"Stelmaszewski","year":"2020","journal-title":"Cardiol. Young-.-."},{"issue":"12","key":"10.1016\/j.phrs.2023.106884_bib116","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1111\/j.1432-2277.2011.01356.x","article-title":"Pregnancy under everolimus-based immunosuppression","volume":"24","author":"Veroux","year":"2011","journal-title":"Transpl. Int"},{"issue":"2","key":"10.1016\/j.phrs.2023.106884_bib117","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1053\/j.ajkd.2012.05.012","article-title":"Pregnancy in a kidney transplant patient treated with everolimus","volume":"60","author":"Carta","year":"2012","journal-title":"Am. J. Kidney Dis."},{"issue":"1","key":"10.1016\/j.phrs.2023.106884_bib118","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.transproceed.2013.09.029","article-title":"Successful maternal and fetal outcome in a kidney transplant patient with everolimus exposure throughout pregnancy: a case report","volume":"46","author":"Margoles","year":"2014","journal-title":"Transpl. Proc."},{"issue":"3","key":"10.1016\/j.phrs.2023.106884_bib119","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/tri.12479","article-title":"Unplanned pregnancies in kidney transplanted patients treated with everolimus: three case reports","volume":"28","author":"Carta","year":"2015","journal-title":"Transpl. Int"},{"issue":"4","key":"10.1016\/j.phrs.2023.106884_bib120","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/ajt.13514","article-title":"First report of a successful pregnancy in an everolimus-treated heart-transplanted patient: neonatal disappearance of immunosuppressive drugs","volume":"16","author":"Fiocchi","year":"2016","journal-title":"Am. J. Transpl."},{"issue":"8","key":"10.1016\/j.phrs.2023.106884_bib121","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1111\/jog.13369","article-title":"Everolimus in pregnancy: case report and literature review","volume":"43","author":"Yamamura","year":"2017","journal-title":"J. Obstet. Gynaecol. Res"},{"issue":"1","key":"10.1016\/j.phrs.2023.106884_bib122","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-021-01913-2","article-title":"Sequential everolimus for angiomyolipoma associated with tuberous sclerosis complex: a prospective cohort study","volume":"16","author":"Gu","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.phrs.2023.106884_bib123","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10147-020-01792-w","article-title":"Efficacy and safety of low-dose everolimus treatment for renal angiomyolipoma associated with tuberous sclerosis complex","volume":"26","author":"Hatano","year":"2021","journal-title":"Int J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.phrs.2023.106884_bib124","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.pediatrneurol.2013.08.002","article-title":"Tuberous sclerosis complex surveillance and management: Recommendations of the 2012 international tuberous sclerosis complex consensus conference","volume":"49","author":"Krueger DA","year":"2013","journal-title":"Pedia Neurol."},{"issue":"6","key":"10.1016\/j.phrs.2023.106884_bib125","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/bjd.12567","article-title":"First left-right comparative study of topical rapamycin vs. vehicle for facial angiofibromas in patients with tuberous sclerosis complex","volume":"169","author":"Tanaka","year":"2013","journal-title":"Br. J. Dermatol."},{"issue":"4","key":"10.1016\/j.phrs.2023.106884_bib126","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/bjd.18949","article-title":"The efficacy and safety of topical rapamycin-calcitriol for facial angiofibromas in patients with tuberous sclerosis complex: a prospective, double-blind, randomized clinical trial","volume":"183","author":"Chen","year":"2020","journal-title":"Br. J. Dermatol."},{"issue":"12","key":"10.1016\/j.phrs.2023.106884_bib127","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1093\/neuonc\/nov152","article-title":"Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex","volume":"17","author":"MacKeigan","year":"2015","journal-title":"Neuro Oncol."},{"issue":"5","key":"10.1016\/j.phrs.2023.106884_bib128","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.jpeds.2013.12.053","article-title":"Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex","volume":"164","author":"Cardamone","year":"2014","journal-title":"J. Pedia"},{"issue":"3","key":"10.1016\/j.phrs.2023.106884_bib129","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s40120-023-00476-7","article-title":"Effect of mTOR inhibitors in epilepsy treatment in children with tuberous sclerosis complex under 2 years of age","volume":"12","author":"\u015amia\u0142ek","year":"2023","journal-title":"Neurol. Ther."},{"issue":"10","key":"10.1016\/j.phrs.2023.106884_bib130","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1468-3083.2011.04212.x","article-title":"Sustained clinical effectiveness and favorable safety profile of topical sirolimus for tuberous sclerosis - associated facial angiofibroma","volume":"26","author":"Salido","year":"2012","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"8","key":"10.1016\/j.phrs.2023.106884_bib131","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180939","article-title":"Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study","volume":"12","author":"Bissler","year":"2017","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.phrs.2023.106884_bib132","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s40263-021-00839-4","article-title":"Efficacy, retention and tolerability of everolimus in patients with tuberous sclerosis complex: a survey-based study on patients\u2019 perspectives","volume":"35","author":"Willems","year":"2021","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.phrs.2023.106884_bib133","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-019-1077-6","article-title":"Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2\u2009years of age - a multicenter retrospective study","volume":"14","author":"Saffari","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"issue":"12","key":"10.1016\/j.phrs.2023.106884_bib134","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1111\/epi.17099","article-title":"Adjunctive everolimus therapy for tuberous sclerosis complex-associated refractory seizures: Results from the postextension phase of EXIST-3","volume":"62","author":"Franz","year":"2021","journal-title":"Epilepsia"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661823002402?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661823002402?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:47:04Z","timestamp":1760914024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661823002402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":134,"alternative-id":["S1043661823002402"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2023.106884","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Paradigm shift in the treatment of tuberous sclerosis: Effectiveness of everolimus","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2023.106884","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106884"}}